Adecatumumab

Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.^[1]

Adecatumumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	EpCAM
Clinical data
ATC code	none
Identifiers
CAS Number	503605-66-1 N
ChemSpider	none
UNII	000705ZASD
Chemical and physical data
Formula	C6552H10080N1740O2052S46
Molar mass	147533.60 g·mol−1
NY (what is this?)  (verify)

Adecatumumab has been used in clinical studies of treatment in colorectal, prostate^[2] and breast cancers.^[3] Phase II results were published in 2010.^[4]